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Osteoclasts differentiate from macrophage-lineage cells to become specialized for bone resorption
function. By a proteomics approach, we found that Lyn was down-regulated by the osteoclast differ-
entiation factor, receptor activator of NF-jB ligand (RANKL). The forced reduction of Lyn caused a
striking increase in the RANKL-induced PLCc1, Ca2+, and NFATc1 responses during differentiation.
These data suggest that Lyn plays a negative role in osteoclastogenesis by interfering with the
PLCc1-mediated Ca2+ signaling that leads to NFATc1 activation. Consistent with the in vitro results,
in vivo injection of Lyn speciﬁc siRNA into mice calvariae provoked a fulminant bone resorption.
Our study provides the ﬁrst evidence of the involvement of Lyn in the negative regulation of osteo-
clastogenesis by RANKL.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Osteoclasts are multinucleated giant cells that are responsible
for bone resorption. Deregulation of osteoclast number and activity
leads to bone diseases such as osteoporosis and osteopetrosis.
Therefore, it is important to identify new molecular targets that
regulate osteoclast differentiation or function for therapeutic pur-
poses. Receptor activator of NF-jB ligand (RANKL) is the essential
factor for osteoclastic differentiation while macrophage colony
stimulating factor (M-CSF) is crucial for precursor proliferation
and cell survival during the differentiation process [1].
The binding of RANKL to its receptor RANK, a member of tumor
necrosis factor receptor (TNFR) superfamily, initiates activation of
signaling pathways that involve recruitment of TNF receptor asso-
ciated factor (TRAF) family proteins and subsequent induction of
the nuclear factor of activated T cells c1 (NFATc1) and other osteo-
clastogenic genes such as tartrate-resistant acid phosphatase
(TRAP) and cathepsin K. NFATc1 is a calcineurin- and Ca2+-regu-
lated transcription factor. Calcium stimulates calcineurin-medi-
ated dephosphorylation of NFATc1 and consequent translocation
of NFATc1 to the nucleus. The calcium signals required for osteo-
clastogenesis may be attained by activation of PLCc [2]. Activated
PLCc hydrolyzes PIP2 to inositol 3-phosphate (IP3) that increases
intracellular Ca2+ and thereby stimulates NFATc1 activation. Induc-
tion of NFATc1 is enhanced by its autoampliﬁcatory property.chemical Societies. Published by E
oo.com (H.-H. Kim).Lyn, a member of the Src family tyrosine kinase, plays a pivotal
role in ligand-induced signaling in B-lineage lymphoid cells [3]. In
B lymphocytes, Lyn phosphorylates the immunoreceptor tyrosine-
based inhibitory motifs (ITIMs), which facilitates the recruitment
of protein tyrosine phosphatase SHP-1 [4]. Whether Lyn plays a
role in osteoclastogenesis has not been investigated to date.
By a proteomic analysis, we found regulation of Lyn expression
by RANKL. We further characterized the role of Lyn in osteoclast
differentiation. Our results indicate that Lyn has a function in
counterbalancing osteoclastogenesis.
2. Materials and methods
2.1. Reagents and antibodies
Anti-Lyn and anti-NFATc1 antibodies were from Santa Cruz Bio-
technology (Santa Cruz, CA). All other antibodies were purchased
from Cell Signaling Technology (Beverly, MA). Human soluble
RANKL and M-CSF were purchased from Pepro-Tech (Rocky Hill,
NJ). Lipofectamine 2000 was from Invitrogen Life Technologies
(Carlsbad, CA). Anti-actin antibody and all other chemicals were
purchased from Sigma (St. Louis, MO).
2.2. Bone marrow-derived macrophage culture and osteoclast
differentiation
Bone marrow-derived macrophages (BMMs) were generated as
described previously [5]. BMMs were cultured in a-MEMlsevier B.V. All rights reserved.
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5 days to generate osteoclasts. Preparation of calvarial osteoblasts
was performed as described [6]. For coculture, calvarial osteoblasts
and BMMs were cultured in the presence of vitamin D3 (108 M)
and PGE2 (106 M) for 6 days. For osteoclast differentiation from
whole bone marrow cells (WBM), cells were ﬂushed out of the
bone marrow cavities with a-MEM. WBM were plated at 1  106
cells per well in 48-well plates and cultured with vitamin D3
(108 M) for 8 days.
2.3. Cell-surface biotinylation and LC/MS/MS experiments
BMMs were surface biotinylated using Pinpoint cell-surface
protein isolation kit (Pierce, Rockford, IL) following the manufac-
turer’s instruction and LC/MS/MS analysis was performed as de-
scribed previously [7].
2.4. Plasmid construct
The entire coding region of the mouse Lyn cDNA was
PCR-ampliﬁed from reverse-transcribed mouse macrophage
cDNA with primers 50-aggatccaccatgggatgtattaaatca-30 and 50-act-
cgagctacggttgctgctgatac-30. Ampliﬁed PCR product was digested
with BamHI/XhoI and cloned into pCMV2B vector.
2.5. Gene knock-down by oligonucleotide siRNA
The 22-nucleotide small interfering RNA (siRNA) duplexes for
Lyn and negative control were purchased from Invitrogen Life
Technologies (Carlsbad, CA). For siRNA transfection, BMMs were
seeded in 48-well plates at a density of 3  104 cells/well.
Twenty-four hours later, 20 pmoles of oligonucleotide siRNA du-
plexes were mixed with 0.5 ll of Lipofectamine 2000 in 200 ll
DMEM and transfected into the cells for 4 h following the manufac-
turer’s instruction.
2.6. Transfection of RAW 264.7
RAW 264.7 cells were seeded in 48-well plates at 1  104 cells/
well. Cells were transfected with 0.4 lg of pCMV2B-Lyn or
pCMV2B plasmids mixed with 1 ll Lipofectamine 2000 and
200 ll DMEM for 4 h following the manufacturer’s instruction.
2.7. RT-PCR
Total RNA was prepared using Trizol (Invitrogen) and cDNAs
were synthesized from 1 lg of RNA using SuperScript II reverse
transcriptase (Invitrogen). The PCR primer sequences used are as
follows: Lyn, 50-tagaagagcatggggaatgg-30 (forward) and 50-
gaaagctcctgcactgttcc-30 (reverse); TRAP, 50-acttccccagcccttactaccg-
30 (forward) and 50-tcagcacatagcccacaccg-30 (reverse).
2.8. Western blotting
Cells were lysed in RIPA buffer containing protease inhibitors.
Whole cell extracts were separated on polyacrylamide gels and
transferred to nitrocellulose membrane. The membrane was
blocked with 5% skim milk and incubated overnight at 4 C with
speciﬁc primary antibodies. The membrane was washed, incubated
for 1 h with a secondary antibody-HRP conjugate, and developed
using an enhanced chemiluminescence system.
2.9. Measurement of intracellular Ca2+ concentrations and oscillation
For measurement of total intracellular Ca2+ concentrations, cells
cultured on plates were loaded with Fluo-4 NW dye solution(Molecular Probes, Eugene, OR) at 37 C for 30 min and then incu-
bated at room temperature for an additional 30 min. The CytoFluor
plate reader (Applied Biosystems, Foster City, CA) was used for
detection with an excitation/emission ﬁlter pair (485/535 nm). To
monitor the Ca2+ oscillation response in individual cells, cells cul-
tured on cover slips were loaded with Fura-2/AM and the assay
was performed as previously described [8].
2.10. In vitro pit formation assay
siRNA-transfected BMMs were cultured on dentin slices for
5 days in the presence of RANKL and M-CSF. The cells were re-
moved by sonication and the dentin slices were stained with 1%
toluidine blue and the bone resorption area was determined with
image analysis software (Image Pro-Plus, Media Cybernetics).
2.11. TRAP staining
Cells were ﬁxed with 3.7% formaldehyde. After washing with
PBS, cells were incubated with 0.1% Triton X-100 for 5 min. Cells
were washed again and stained for TRAP activity for 40 min at
37 C in dark using the Leukocyte Acid Phosphatase Assay kit (Sig-
ma) following the manufacturer’s instruction. TRAP staining of
mice calvariae was also performed in the same way.
2.12. Calvarial bone resorption assay
Thirty microliters of 20 lV Lyn speciﬁc siRNA or scrambled con-
trol siRNA were mixed with 10 ll of Lipofectamine 2000 and in-
jected onto calvariae three times with 2-day intervals. One day
after the ﬁrst injection, collagen sheet soaked with 10 lg of RANKL
or PBS and implanted into the center of calvariae. Mice calvariae (5
per group) were collected and micro-computed tomography (l-CT)
was performed with 1072 Microtomograph (SkyScan, Belgium).
Histological sections were generated after decalciﬁcation and
embedding into parafﬁn and the sections were stained for TRAP
activity. To evaluate in vivo gene silencing by Lyn siRNA, total
RNA was extracted from calvariae and RT-PCR analyses were
performed.3. Results
In an attempt to discover new molecules involved in the regu-
lation of osteoclast differentiation, the proﬁle of membrane pro-
teins expressed in macrophages and osteoclasts was compared.
Following cell surface biotinylation of bone marrow-derived mac-
rophages (BMMs) cultured with or without RANKL for 36 h, biotin-
ylated proteins were isolated and subjected to SDS–PAGE. As
shown in Fig. 1A, several protein bands showed differential expres-
sion upon RANKL treatment. Those protein bands were cut out and
processed for liquid chromatography followed by tandem mass
spectrometry. We identiﬁed a protein from 55 kDa band of which
density apparently decreased by RANKL as Lyn (Fig. 1B and C). To
conﬁrm the reduced expression of Lyn by RANKL, BMMs treated
with or without RANKL in the presence of M-CSF were subjected
to RT-PCR and Western blotting. Fig. 1D shows that Lyn mRNA
and protein levels were decreased by RANKL treatment for 24 h.
Next, we investigated whether the activity of Lyn may be regulated
by RANKL. Since tyrosine phosphorylation of Lyn correlates well
with the catalytic activity of Lyn, we measured Lyn tyrosine phos-
phorylation in BMMs stimulated with RANKL plus M-CSF for
30 min. As shown in Fig. 1E, the tyrosine phosphorylation of the
53 and 56 kDa bands of Lyn immunoprecipitates increased upon
stimulation. This result indicates that the catalytic activity of Lyn
is stimulated by osteoclastogenic signal.
Fig. 1. Proteomic analysis of Lyn expression on osteoclasts. (A) BMMs were incubated with 30 ng/ml M-CSF plus 200 ng/ml RANKL for 36 h followed by biotinylation of
surface proteins. The biotinylated proteins were separated on an 8–16% SDS gel. The protein bands were visualized by staining with SYPRO Ruby. (B) The protein band
indicated by an arrow in (A) was digested with trypsin and subjected to LC/MS/MS analysis. The proﬁle of peptides eluted from LC is shown. The peak indicated with a circle
was identiﬁed as a peptide of Lyn. (C) The sequence of the Lyn peptide obtained by mass spectrometry is presented. (D) BMMs were cultured with 30 ng/ml M-CSF plus
200 ng/ml RANKL for 24 h. The expression levels of Lyn mRNA and protein were determined by RT-PCR and Western blotting. (E) Whole cell extracts from RANKL stimulated
BMMs were immunoprecipitated with control rabbit IgG or Lyn antibody followed by Western blotting using phospho-tyrosine or Lyn antibody. HC: heavy chain of antibody.
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ment, we investigated the functional role of Lyn for osteoclasto-
genesis by gene knock-down. BMMs were transfected with Lyn
speciﬁc siRNA or scrambled control siRNA oligonucleotide du-
plexes. The efﬁciency of gene silencing was assessed by RT-PCR
and Western blotting. Both the mRNA and protein levels of Lyn
were decreased in Lyn siRNA-transfected BMMs compared with
scrambled siRNA-transfected cells (Fig. 2A). Next, to evaluate the
effect of Lyn silencing on osteoclastogenesis, the siRNA-transfected
BMMs were cultured with RANKL plus M-CSF for 5 days and
stained for TRAP activity. The number of TRAP+ osteoclasts gener-
ated from Lyn siRNA-transfected BMMs was strikingly higher than
that from control cells (Fig. 2B, top panel). When the siRNA-trans-
fected BMMs were induced to differentiate by coculturing with cal-
varial osteoblasts, similar results were obtained (Fig. 2B, middle
panel). Furthermore, the pro-osteoclastogenic effect of Lyn
knock-down was also evident when whole bone marrows cells
were transfected with siRNA and osteoclastogenesis was induced
(Fig. 2B, bottom panel). We also assessed the effect of Lyn silencing
on osteoclastogenesis by evaluating the resorption activity of
osteoclasts generated from Lyn silenced or control siRNA-transfec-
ted BMMs in vitro. As shown in Fig. 2C, the area of resorption pits
produced on dentine slices with Lyn silenced-BMMs was greater
than that with control siRNA-transfected cells. Next, we examined
the effect of Lyn overexpression on osteoclastogenesis. RAW 264.7
cells were transfected with Lyn or a control plasmid and culturedwith RANKL. Lyn overexpression resulted in an evident decrease
in the number of osteoclasts generated (Fig. 2D). All of these results
demonstrate that Lyn plays a negative role for osteoclast
differentiation.
To gain molecular insights into the suppressive role of Lyn in
osteoclastogenesis, we investigated the effect of Lyn silencing on
RANKL-induced signaling pathways. MAPK signaling cascade is
one of the well-characterized pathways activated by RANKL.
Therefore, we assessed the activation of MAPKs (p38, Erk1/2,
JNK) in Lyn silenced-BMMs. There was no signiﬁcant difference
in the phosphorylation of MAPKs between Lyn siRNA- and control
siRNA-transfected cells upon RANKL stimulation (data not shown).
On the other hand, phosphorylation of PLCc1 was conspicuously
enhanced in Lyn silenced-BMMs compared with control cells
(Fig. 3A). PLCc activation leads to generation of IP3 that evokes
Ca2+ signal, which is required for activation and induction of
NFATc1 in osteoclasts [2]. Therefore, we examined the RANKL-in-
duced Ca2+ signal in Lyn silenced-BMMs, which is crucial for
autoampliﬁcation of NFATc1 during osteolcast differentiation. As
shown in Fig. 3B, the total intracellular Ca2+ concentration was ele-
vated in Lyn silenced-BMMs compared with scrambled siRNA-
transfected cells. Furthermore, the amplitude and frequency of
Ca2+ peaks in the oscillation response of individual cells were also
signiﬁcantly higher in Lyn siRNA-transfected cells (Fig. 3C). To
examine the effect of increased Ca2+ signaling by Lyn depletion
on NFATc1, we assessed the expression level of NFATc1 in Lyn si-
Fig. 2. Effect of Lyn silencing on osteoclast differentiation. (A) BMMs were transfected with scrambled siRNA or Lyn siRNA. After 24 h, the levels of Lyn mRNA and protein
were analyzed. (B) siRNA-transfected BMMs were incubated with RANKL (top panel) or cocultured with calvarial osteoblasts (middle panel) for 5 days and then TRAP stained.
siRNA transfected whole bone marrow cells (WBM) were differentiated for 8 days in the presence of vitamin D3 and then TRAP stained (bottom panel). The number of TRAP+
multinucleated cells was scored. (C) Lyn or control siRNA-transfected BMMs were placed on dentine slices and cultured in the presence of RANKL for 5 days. The resorbed pit
area was assessed after removing cells and staining with toluidin blue. (D) RAW 264.7 cells were transfected with pCMV or pCMV-Lyn. After 24 h, the cells were cultured with
RNAKL for 3 days and then TRAP stained. The number of TRAP+ multinucleated cells was scored.
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in Lyn siRNA-transfected cells compared to the control siRNA-
transfected cells. Taken together, these results suggest that Lyn
inhibits RANKL-induced NFATc1 activation by suppressing PLCc-
mediated Ca2+ oscillation during osteoclast differentiation.
Next, we examined upstream events of the Lyn-mediated cal-
cium signaling. c-Src is a molecule reported to be crucial to calcium
signaling for osteoclastogenesis and Syk serves a substrate of c-Src
kinase in the calcium signaling cascade [9]. We found that the c-Src
phosphorylation induced by RANKL stimulation was greater in Lyn
silenced-BMMs (Fig. 3E). Furthermore, Lyn was co-immunoprecip-
itated with Syk (Fig. 3F). These results suggest that Lyn may regu-
late osteoclastogenesis by restraining the c-Src-mediated calcium
signaling.With the in vitro evidence that Lyn plays a negative function in
osteoclastogenesis, we next evaluated the role of Lyn in vivo. Mice
calvariae were implanted with collagen sheets soaked with either
RANKL or PBS. Lyn speciﬁc siRNA or control scrambled siRNA
was injected into the calvariae trice with a 2-day interval and
stained for TRAP activity. As shown in Fig 4A, Lyn mRNA level
was lower in Lyn siRNA-injected calvariae than compared with
that in control siRNA-injected mice. We also observed elevated
TRAP mRNA levels in Lyn silenced calvariae (Fig. 4A). Furthermore,
calvariae of Lyn siRNA-injected mice revealed an increased number
of TRAP-positive osteoclasts compared with the control siRNA-in-
jected mice both in RANKL and PBS administration conditions
(Fig. 4B). Consistently, l-CT analysis showed a signiﬁcantly re-
duced bone volume in Lyn siRNA-injected calvariae compared with
Fig. 3. Inhibition of RANKL-induced PLCc and Ca2+ signaling by Lyn silencing. (A) siRNA-transfected BMMs were cultured with RANKL and M-CSF for 2 days. Cells were serum
starved for 5 h and re-stimulated with RANKL (200 ng/ml) for 40 min. Cell lysates were subjected to Western blotting. (B) siRNA-transfected BMMs were seeded in culture
plates, incubated with RANKL plus M-CSF for 2 days, and loaded with Fluo-4 NW. The total ﬂuorescence of wells was measured using a plate reader. (C) siRNA-transfected
BMMs were placed on cover slips and cultured with RANKL plus M-CSF for 2 days. Cells were loaded with Fura-2/AM and the in situ Ca2+ oscillation response of each cell was
monitored using a confocal microscope. (D) siRNA-transfected BMMs were cultured with RANKL and M-CSF for 2 days. The levels of NFATc1 and Lyn were determined by
Western blotting. (E) siRNA-transfected BMMs were cultured with RANKL and M-CSF for 2 days. Cell lysates were immunoprecipitated with c-Src antibody and Western
blotted with phospho-c-Src antibody. (F) BMMs were stimulated with RANKL for the indicated time points. Cell lysates were immunoprecipitated with Lyn antibody and
immunoprecipitates were subjected to Western blotting with Syk and Lyn antibodies.
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hold the in vitro stimulatory effect of Lyn siRNA on osteoclast
differentiation.
4. Discussion
It has been well recognized that RANKL stimulates the activa-
tion of intracellular signaling molecules for expression of genes
essential for osteoclast differentiation. A few reports indicate that
negative regulatory signaling for osteoclastogenesis is also acti-
vated upon RANKL stimulation [10]. However, the mechanism of
negative regulation is largely unknown. By a proteomics approach
using BMMs, we found that the protein level of Lyn was reduced by
RANKL treatment. We further characterized the role of Lyn in
osteoclast differentiation by gene knock-down. Introduction of
Lyn siRNA greatly increased the formation of osteoclasts from pri-
mary precursor cells in vitro through a mechanism involving PLCc
and Ca2+ oscillation. The pro-osteoclastogenic effect of Lyn siRNA
was conﬁrmed in vivo by experiments using a mouse calvarial
model of bone resorption. Our results implicate that Lyn is a bona
ﬁde negative regulator in RANKL-induced osteoclastogenesis.It has been reported that Lyn has an inhibitory function in B cell
antigen receptor (BCR) signaling by directly phosphorylating Syk at
an inhibitory tyrosine residue [3]. Alternatively, Lyn may phos-
phorylate ITIM motif tyrosines in inhibitory receptors like PIR-B
and FcRIIB for recruitment of phosphatases that dephosphorylate
Syk and Btk, two key molecules required for BCR signaling [11].
One of the signaling events evoked by BCR is activation of PLCc
by Syk and Btk, and subsequent Ca2+ mobilization [11]. Since
RANKL also activated PLCc and Ca2+ signals, we postulated that
Lyn might participate in RANKL signaling. Our data demonstrated
that Lyn gene knock-down in osteoclast precursor cells enhanced
PLCc activation and Ca2+ signals, suggesting an analogy present be-
tween BCR and RANK signal transduction processes. Indeed, the
ITIM-harboring inhibitory receptors LILRB and PIR-B were recently
reported to negatively regulate osteoclastogenesis [12]. Whether
Lyn-mediated phosphorylation of those ITIM motifs is involved in
the inhibition of osteoclastogenesis by Lyn is therefore an intrigu-
ing question.
Syk has been implicated for the regulation of osteoclast differ-
entiation. Syk-deﬁcient BMMs fail to differentiate to mature osteo-
clasts and show defect in bone resorbing activity [13]. Recently, it
Fig. 4. In vivo effects of Lyn silencing on bone resorption. (A–C) Mice calvariae were injected with Lyn siRNA or scrambled siRNA three times with a 2-day interval. One day
after the ﬁrst injection, mice calvariae were implanted with collagen sheets soaked with RANKL or PBS. mRNA was collected from calvariae and the levels of Lyn and TRAP
were determined by RT-PCR (A). Calvariae were decalciﬁed and processed for TRAP staining as described in Materials and methods (B). Undecalciﬁed calvariae were scanned
with a l-CT and analyzed for bone volume (C). *P < 0.05 between PBS and RANKL groups and P < 0.05 between control siRNA and Lyn siRNA groups.
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phosphorylation and induces osteoclastic bone resorption [9]. We
observed that Lyn was co-immunoprecipitated with Syk in BMMs
and the interaction was increased by RANKL stimulation. There-
fore, it is possible that Lyn inhibits osteoclast differentiation by a
mechanism relying on Syk. We also found that Lyn silencing in-
creases phosphorylation of c-Src in BMMs. It is known that Lyn re-
cruit phosphatases such as SHP-1 and SHIP-1 in neutrophils [14].
Thus, a potential mechanism by which Lyn negatively regulates
osteoclast differentiation is recruitment of phosphatases to Src
and Syk in response to RANKL stimulation. Understanding the se-
quence of phosphorylation of these kinases by one another and
recruitment of phosphatases upon RANKL stimulation requires fur-
ther investigation.
It has been well established that Lyn play an important role in
regulating BCR signaling. Lyn knock-out mice display disrupted
B-cell function and defective mast cell degranulation [15,16]. How-
ever, skeletal phenotypes of Lyn deﬁcient mice have not been re-
ported and role of Lyn in bone cell regulation has not beeninvestigated. Our in vitro and in vivo data provide the ﬁrst line of
evidence that Lyn has an anti-osteoclastogenic function. Further
studies with Lyn knock-out mice may generate corroborative evi-
dence for the involvement of Lyn in osteoclastogenesis regulation.
Our study suggests that increasing Lyn activity or expression level
may be a useful strategy in developing therapeutics for treating
bone lytic diseases.Acknowledgements
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